Interim Results of a Prospective Phase 2 Trial of Pelvic IMRT, Cesium-131 Brachytherapy Boost, Adjuvant Docetaxel Chemotherapy, and Long-term Androgen Ablation for Patients With High-Risk Prostate Cancer

Abstract

Despite aggressive therapy more than 50% of patients with high-risk prostate cancer fail biochemically. We instituted a phase II protocol which attempts to improve on these results by adding a brachytherapy boost, designed to further increase the prostate dose and docetaxel to address possible systemic disease. The following describes the interim results of patients who have been off of all therapy.